Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Input metadata referenced "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2000
Status: Development stage enterprise focused on proprietary pulmonary delivery technologies (MSI, ADDS, UPDAS). The company has generated minimal revenue and sustained significant net operating losses since inception in 1986.
Key Financial Metrics
| Metric | Q1 2000 | Q1 1999 | Inception to Mar 31, 2000 |
|---|---|---|---|
| Total Revenues | $121,170 | $26,000 | $1,880,548 |
| Net Loss | $(1,457,090) | $(1,162,656) | $(73,480,128) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.04) | $(8.87) |
| Cash and Cash Equivalents (End of Period) | $3,487,892 | $1,908,615 | N/A |
| Net Cash Used in Operating Activities | $(1,818,690) | $(1,092,641) | $(66,844,298) |
| Total Assets | $6,361,042 | N/A | N/A |
| Total Liabilities | $4,148,795 | N/A | N/A |
| Stockholders' Equity | $2,212,247 | N/A | N/A |
Debt and Liquidity: The company holds a $2,000,000 convertible promissory note. Cash balances decreased by $386,545 during the quarter, primarily due to operating cash outflows of $1.82 million, partially offset by $1.47 million in proceeds from the exercise of stock options and warrants.
Material Changes vs. Prior Period
- Revenue Growth: Contract research revenue increased to $121,170 from $26,000 in the prior year quarter, driven by three additional respiratory programs in development.
- Expense Increases:
- R&D Expenses: Rose to $902,023 from $680,979, primarily due to modifications to the Metered Solution Inhaler (MSI) for Phase III trials.
- G&A Expenses: Increased to $694,724 from $499,663, attributed to higher consulting and legal fees for business development.
- Interest Income: Doubled to $52,501 from $21,877 due to larger cash balances and higher investment yields.
- Interest Expense: Increased to $50,033 from $29,891 due to higher outstanding balances on the convertible note with Elan.
Outlook, Risks, and Management Commentary
- Capital Requirements: Management states the company requires substantial additional capital to fund operations and development. Future funding is expected to come from equity/debt offerings, out-licensing, or collaboration agreements.
- Strategic Alliances:
- Zambon Group: Sublicensed MSI commercial rights for respiratory products; Zambon funds development costs and makes milestone payments. A $1,000,000 interest-free advance was received in 1999, repayable if milestones are not met.
- Elan Corporation: Joint venture (RSD) formed for inhaled steroid products. Elan committed to purchase up to $4,000,000 of Series E Preferred Stock (none purchased as of March 31, 2000).
- Risks: No assurance that technologies will be commercialized or generate sufficient revenue. Development programs may be curtailed if future financing is not secured. The company does not expect significant cash flow from operations for at least the next few years.
Investor Verification Checklist
- Verify the status of the $1,000,000 interest-free advance from Zambon and the specific milestones required to convert it to revenue.
- Confirm the timeline and funding status for the Phase III MSI-albuterol clinical trials.
- Assess the likelihood of Elan exercising its option to purchase the additional $4,000,000 of Series E Preferred Stock.
- Review the terms of the $2,000,000 convertible promissory note to understand conversion triggers and interest obligations.
- Monitor cash burn rate relative to the current cash balance of ~$3.5 million to estimate runway without new financing.